Article and Video CATEGORIES
Continuing with our post-ASCO highlights presentation, we now turn to Dr. Joel Neal, Assistant Professor at Stanford Cancer Center, who covered several targeted therapy options that are still working their way through investigational work. There were several promising agents reported as potential treatments for lung cancer, but perhaps none was more exciting than anti-PD-1 immunotherapy that was described by Dr. Julie Brahmer in a podcast from a few months ago. She actually led and presented the work on anti-PD-1 in lung cancer at ASCO, but she wasn't able to share her exciting early results prior to ASCO. Dr. Neal provides both some background and a summary of the results that were so encouraging to the lung cancer community.
Below you'll find the video and audio versions of the podcast, along with the transcript and figures.
Dr. Neal ASCO 2012 LC Highlights Anti-PD-1 Audio Podcast
Dr. Neal ASCO 2012 LC Highlights Anti-PD-1 Figs
Dr. Neal ASCO 2012 LC Highlights Anti-PD-1 Transcript
So how encouraged are you by these results?
We'll continue with other novel therapies presented at ASCO 2012 and summarized by Dr. Neal in our next podcast.
In the meantime,
Please feel free to offer comments and raise questions in our
Next Previous linkPrevious PostNext Post
The forum was a big success. If you weren't able to attend the live session we'll have an on-demand version available soon.
If you have questions that weren't addressed please ask...
Hi Everyone, I'm glad you have found this thread and sorry that you need to be here.
We've got the forum up for on-demand streaming. This full version will be...
Hi JGromo, Welcome to Grace. I'm so sorry your dad and by extension, you are going through this. If it helps, I know how you feel. My husband is going through...
I agree that not all docs are good communicators! Remember they are people just like us, filling a very important role. I echo Janine's comment to ask questions here -- our...
While no one can give advice or recommend treatments on a forum our faculty can be invaluable when talking about current thought and practices.
This is the response via email...
I wanted to…